- Zacks•13 hours ago
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).
- PR Newswire•3 days ago
INDIANAPOLIS, Jan. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review ...
- Investor's Business Daily•3 days ago
Incyte's oncology program will grow on a Merck partnership tying Keytruda and epacadostat in four "hot" tumors in 2017.
INCY : Summary for Incyte Corporation - Yahoo Finance
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||86.00 x 100|
|Ask||119.75 x 100|
|Day's Range||116.72 - 119.80|
|52 Week Range||55.00 - 121.18|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||319.97|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|